Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), I. Valente (Parma, Italy), A. Guasconi (Parma, Italy), H. Prunier (Parma, Italy), G. Georges (Cary, United States of America), A. Papi (Ferrara, Italy). Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study. 2130

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Effect of triple therapy with extra-fine BDP/FF/GB pMDI during seasonal peaks of asthma exacerbations. A post-hoc analysis of the TRIMARAN and TRIGGER studies Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 LATE-BREAKING ABSTRACT: Association of incident pneumonia and exacerbations with extrafine beclometasone dipropionate/formoterol (BDP/FF) in severe COPD patients: A post-hoc analysis of FORWARD study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Effect of extrafine medium strength (MS) ICS-containing triple therapy on exacerbations in asthmatics with persistent airflow limitation: A post-hoc analysis of the TRIMARAN study Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2018 – Variant forms of asthma Year: 2018 Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016